Revenue - Condensed Statement Of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Development and Collaboration Agreement
Revenue from collaborative arrangements	$ 26,464	$ 31,245	$ 130
Viatris collaboration agreement
Development and Collaboration Agreement
Revenue from collaborative arrangements	$ 43,893	13,664	3,275
Collaboration Loss		1,582	2,997
YUPELRI Monotherapy
Development and Collaboration Agreement
Percentage of net sales	35.00%
YUPELRI Monotherapy | Viatris collaboration agreement
Development and Collaboration Agreement
Revenue from collaborative arrangements	$ 3,700	$ 19,300	$ 50,000
Percentage of net sales	35.00%	35.00%	35.00%